Research Article

A novel theranostics nanoparticles pGGA-PTX / SPION with bifunction of diagnosis and treatment

Jing Wang¹, Mingxue Fan¹, Lin Han¹, Zhiqiang Yan¹, Yiting Wang¹*, Lei Yu¹, Hui Peng²,³ and Jianzhong Zhu¹,*

¹Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University
²Key Laboratory of Polar Materials and Devices, Ministry of Education, Department of Electrical Engineering, East China Normal University, Shanghai, China
³Collaborative Innovation Center of Extreme Optics, Shanxi University, Taiyuan, Shanxi 030006, China

ARTICLE INFO

Article history:
Received 10 October, 2018
Accepted 2 November, 2018
Published 5 November, 2018

Keywords:
Polymer delivery system
diagnosis and treatment
nanoparticles
contrast agent
PTX (Paclitaxel)

ABSTRACT

To increase the solubility of free drugs, drug-loaded efficiency and prolong the half-life of drugs in the body, a novel theranostics nano-particles, pGGA-PTX / SPION with a good diagnosis and treatment function have been fabricated. It is plump and uniform in size, to 113.0 ± 0.6nm, leading to the passive targeting of tumor tissue due to the EPR effect. The content-loaded of PTX was about 27.66%. The contrast agent content was about 6.34%. In vitro evaluation such as cell viability, the pGGA-PTX / SPION NPs were similar to that of PTX, suggesting a useful anticancer effect on tumor cells. In the H&E experiment, the pGGA-PTX / SPION did not impair the normal tissue and fully proved its safety performance. In vivo imaging, the pGGA-PTX / SPION in the tumor body can clearly be observed by NMR, to achieve real-time monitoring of drugs. In vivo treatment effects experiment, the pGGA-PTX / SPION exhibits a significant tumor growth inhibition effect.

Introduction

Modern clinical medicine has gradually developed from the traditional "one-size-fits-all" to the new individualized treatment strategy. Advances in nanotechnology provide a possibility to integrate the diagnostic reagents and treatment reagents in a single system, which allows the doctor to reduce the time between diagnosis and treatment [1-5]. Among nanomaterials, the functionalized nanoparticles (NPs) play an important role in the field of individualized treatment [6-9]. Typical representatives are quantum dots as fluorescence imaging agent and magnetic NPs as nuclear magnetic resonance imaging agent (NMRI) [10-15]. The latter includes ferromagnetic iron oxide NPs and superparamagnetic iron oxide NPs (SPION) [16-20]. They exhibit distinct passive targeting to tumor tissue. In order to help facilitate the delivery
in the body and prolong the circulation time of NPs, NPs are usually wrapped by polymers due to the improvement in the pharmacokinetics parameters of NPs [23-26]. Polymers are used as coating includes polyethylene glycol (PEG), dextran, chitosan, polyethyleneimine (PEI) and phospholipids [27-31].

A successful nanodrug delivery system can prolong the circulating time of the drug in the body, enter the target cells, and release it through the regulatory mechanism within the cells [32]. In order to reduce the time between diagnosis and treatment of patients and improve the efficiency of treatment, many drugs are combined with magnetic NPs, including paclitaxel (PTX), doxorubicin and methotrexate [32-35]. Although the polymer-based contrast agent and the drug delivery system have been widely investigated, reported platform systems still have the following problems needed to be solved: (1) the preparation process is complex and time-consuming. Furthermore, large-scale production and reproducibility are still in question; (2) minimal loading of contrast agents and drug, and (3) biocompatibility of coating materials needed to be further improved.

PGGA-PTX is a modification of poly (L-glutamic acid)-paclitaxel conjugate (PGA-PTX) in which an additional glutamic acid has been added to each glutamic side chain. PGGA-PTX has higher water-solubility and faster dissolution than PGA-PTX. Unlike PGA-PTX, PGGA-PTX self-assembles into NPs. However, PGGA-PTX possesses lower toxicity compared with PGA-PTX in mice [40]. In this work, we encapsulated the contrast agent, SPION, by drug-loading polymer, PGGA-PTX through a simple emulsification method to construct a diagnostic and treatment system. This system shows advantages of high loading of drug, enhancement of tumor inhibition and reduction of the toxicity. Moreover, we can easily real-time monitor where the drug gathered, drug content in the tumor and metabolic situation.

Experimental

I Materials

PGA-PTX, SPION and pentobarbital sodium were bought from Sigma-Aldrich Co. Ltd, US. Sodium cholate was acquired from Acros Co. Ltd., Belgium. CCK-8 kit was obtained from the Boster Biological Technology Co. Ltd. Balb/c male nude mice (age 5 weeks) was supplied by the Institute of Brain Function, East China Normal University. U87 cell line (40 and 60 generations) was acquired from Shanghai Life Cell Library, Chinese Academy of Sciences.

II Preparation of pGGA-PTX / SPION NPs

PGG-PTX is a modification of poly (L-glutamic acid)-paclitaxel conjugate (PGA-PTX) in which an additional glutamic acid has been added to each glutamic side chain in the polymer. The synthesis of PGGA-PTX was carried out in accordance with reference [40]. 25g of pGGA-PTX was dissolved in 10 mL of 0.5% sodium cholate solution under stirring to give a clear colorless aqueous solution of pGGA-PTX. The methylene chloride and acetone were fully mixed together in a volume ratio of 1:2. The SPION solution dispersed in toluene was added to 20 mL of a mixture of methylene chloride and acetone. Subsequently, the formed oil phase solution was dropwise added to the aqueous pGGA-PTX solution under stirring, followed by ultrasonication until the milky droplets gradually disappear. The color of the solution gradually changed from brown to light yellow. The mixture was placed in a rotary vial to remove acetone at 35℃. The obtained mixture was sonicated at room temperature for 20 min. After removing the solvents by freeze-drying, milky white and flocculent pGGA-PTX/ SPION NPs were obtained.

III Characterization

The morphology of the SPION, pGGA-PTX and pGGA-PTX/SPION NPs was characterized by a HRTEM (Hitachi H-9000). Particle size of three NPs was determined by laser particle analyzer, Mastersizer 2000 (Malvern Instrument LTD, UK). The amounts of PTX and SPION in pGGA-PTX/SPION were determined by UV spectrophotometer (OLYMPUS IMAGING) and ICP-MS (Perkin Elmer ELAN, US). The stability and weight loss of the three NPs were quantitatively determined by thermo-gravimetric analyzer (TA Instruments Q500, US). Cell counter and Millicell-ERS volt-ohmmeter (Merck Millipore), high performance liquid phase chromatography (HPLC) (shimadzu Co., LTD, Japan), Freezing microtome (Leica), Multiskan MK3 Automatic enzyme standard instrument, Embedded culture wells, Transwell Millipore Ltd. Co., Cell resistance meter, Millipore and the cell constant temperature incubator (Thermo Fisher Scientific) and NMI (Siemens Healthcare Erlangen, German) were used for relevant test.

IV Animal test

Male nude mice aged about 5 weeks were randomly classified into three groups. Eight rats in each group were inoculated with glial tumor tissue in the armpit area of about 2 × 2 × 2 mm3. Three groups of mice were grown under the same conditions. When the tumor volume was about 100 mm3, the mice were injected into three groups through the tail vein. The concentration of PTX was 1.5mg/ml in the experimental group and the control group were received a tail vein injection of the same amount of normal saline. Within the next 16 days, the volume of the tumor was measured with a vernier caliper every 2 days. The volume of the tumor is calculated as 1/2 (width × length).

Results and Discussion

I Structure of the pGGA-PTX/SPION

PTX loading polymer can self-assemble into NPs, which can encapsulate contrast agent SPION to integrate into a shell core structure of pGGA-PTX/ SPION NPs, as depicted in Scheme 1. Its shell surface is hydrophilic, and the core is hydrophobic. It exhibits some passive targeting to tumor tissue in several degree due to the EPR effect. These features will be confirmed by subsequent TEM studies.

Scheme 1 Synthesis and structure of the pGGA-PTX/SPION.
II The morphologies of the NPs

The TEM results show that all NPs are spherical. The particle sizes of SPION is about 9nm (Fig. 1 A). Due to the hydrophobic side chains, pGGA-PTX is self-assembled to form nanoparticles with a size of ~ 60 nm, as shown in Fig. 1 B. In Fig. 1 D, we can find that the SPION evenly distributed in the pGGA-PTX / SPION core, thus microscopically proved that due to SPION makes pGGA-PTX / SPION particle size increases slightly larger than PGGA-PTX NPs. Fig. 1 D is a partial enlarged picture of Fig. 1 C.

III Size distribution

In the field of pharmaceutical research and development, the particle size range of NPs is extremely important for the passive targeting of drugs. Tumor vascular tissue structure has a distinct structure, which is referred to the EPR effect. The EPR effect is the high permeability of the solid tumor in vivo and the retention effect. The direct effect of tumor EPR effect is that the vascular permeability in the tumor tissue is higher than that in the normal tissue, and the incompleteness is indicated. By using the speciality of the tumor, the NPs enter tumor more easily than that of the normal tissue, resulting in a therapeutic effect while reducing side effects on non-targeted cells. In this experiment, particle size of the pGGA-PTX/SPION prepared is about 113.03 ± 0.6 nm (Figure 2 and Table 1), within the particle size range for the EPR effect. It has a nice passive targeting effect, and further speaking, the NPs reduce the non-targeted cell toxicity, improve safety.

Table 1: Size, PDI, ζ potential, and LE of three NPs: SPION, pGGA-PTX and pGGA-PTX/SPION.

| Sample     | SPION size (nm) | pGGA-PTX size (nm) | pGGA-PTX/SPION size (nm) |
|------------|-----------------|--------------------|--------------------------|
|            | 8.02±1.07       | 66.62±1.36         | 113.03±0.6               |
| PDI        | 0.22            | 0.21               | 0.17                     |
| ζ potential (mV) ± SD | -12.04±1.06 | -30.00±2.00        | -25.33±3.06              |
| PTX LC (%) ± SD | 35.6       | 27.66              |                          |
| SPION LE (%) ± SD | 51.61±4.99 |                  |                          |
| SPION LC (%) ± SD | 6.34±0.62      |                    |                          |

IV Drug loading capacity and SPION content in the NPs

The encapsulation efficiency and loading of SPION were measured by ICP-MS after acidification. The encapsulation efficiency and loading of SPION were 51.61 ± 4.99 and 6.34 ± 0.62, respectively (Table 1). Compared with other materials wrapped SPION which can be observed in the results of high LC%. The LC% (35.6%) of pGGA-PTX was higher than the LC% (27.66%) of pGGA-PTX / SPION by HPLC, which was due to the relative decrease in the proportion of PTX owing to the presence of SPION.

V Stability of the PGGA-PTX and pGGA-PTX/SPION

Figure 3 shows the TED curves for three NPs: SPION (A), pGGA-PTX / SPION (B) and pGGA-PTX (C). The weight loss of SPION NPs is not discernible with the increase of temperature. There is a little increase in the weight loss when the temperature is higher than 300 °C, which may be due to oxidation of SPION by the existed small amount of oxygen. PGGA-PTX and pGGA-PTX / SPION are not significantly changed when the temperature is lower than 100 °C, indicating that the NPs are considerably stable. When the temperature reached 150 °C, the polymer started to decompose. Until 500 °C the curve tends to be stable, and at 800 °C the decompostion was finished. The final weight of the C curve is about 31.5 wt %, the B curve is 36.0 wt %. It can also be calculated that the multifunctional NPs contain a specific gravity of 6.2% by weight of SPION, confirming the previous SPION carrying capacity (6.34 wt %) measured by ICP.
A novel theranostics nanoparticles pGGA-PTX / SPION with bifunction of diagnosis and treatment

VI Cytotoxicity tests

Cytotoxicity experiments were performed using the CCK-8 kit (Refer Supplement 3). As showed in Fig. 4, the three experimental groups showed a decrease in the survival rate of the cells as the concentration of PTX increased. The overall survival rate of PTX group was comparable to that of pGGA-PTX / SPION. According to the latest study, SPION itself was not toxic and had no cytotoxic effect on cell level at cell level, but probably because of the physical properties of nanoparticles after SPION encapsulation changes, including the size of the particle size and the role of chemical bonds. pGGA-PTX makes PTX easier to separate from the high molecular skeleton, so the inhibition of U87 UGG effect is similar to that of PTX group. Compared to the two other groups, PGGA-PTX shows slightly lower capability to suppress tumor cells, which be due to not every PTX molecule in pGGA-PTX acts with the tumor cells. This will lead to no equivalent amount of PTX in the PGGA-PTX group.

VII TEM images

We can observe from (Figure 5) that the black SPION particles are not found in the control group A and B because of the saline was added to the samples. In the experimental group C, we can clearly see black spherical particles in the cytoplasm and organelles. By analyzing the particle size and morphology, we can conclude that the black particles in the area marked with a yellow border are pGGA-PTX / SPION particles (Figure 5C). Fig. 5D is an enlarged picture of (Figure 5 C). Therefore, it clearly illustrates that the pGG-PTX / SPION can enter tumor cells at the microscopic level.
sometimes pGGA-PTX / SPION will be better. Tumor inhibition effect for pGGA-PTX / SPION and pGGA-PTX may be caused by their EPR effect, while can reduce the toxicity of non-target tissue. The results therefore confirmed the conclusion of the cytotoxicity test.

**IX MRI imaging for nude mice inoculated U87 cell**

In order to further validate the results obtained from froze section imaging, MRI imaging experiments of living animals were performed. The expression of pGGA-PTX / SPION in the tumor was observed after tail vein injection of pGGA-PTX / SPION at 0h, 0.5h, 1h, 2h, 4h, 12h, 24h and 48h, respectively. It can be observed in (Figure 8) that T2 signal was not detected in the tumor when pGGA-PTX / SPION was just injected into the tail, indicating that pGGA-PTX / SPION did not reach the tumor site. After 0.5 h of injection, a little of the dark can be observed in the tumor. After 4h, T2 signal reached maximum, indicating that the maximum accumulation of pGGA-PTX / SPION in the tumor. From the 4h to 48h, the tumor gradually brightened, indicating that the drug metabolism in the tumor until finished. After 48h from this experiment we can find that, due to the existence of SPION, it is more easily grasp whether the drug gathered in the target site and real-time monitoring of drug content in the tumor and metabolic situation [42].

**Conclusion**

A novel theranostics nanoparticles, pGGA-PTX / SPION with a good diagnosis and treatment function has been fabricated. It is plump and uniform in size, about 113.0 ± 0.6 nm, leading to the passive targeting of tumor tissue due to the EPR effect. The content-loaded of PTX was about
A novel theranostics nanoparticles pGGA-PTX / SPION with bifunction of diagnosis and treatment cell imaging and photodynamic therapy, Biosensors and Bioelectronics, 2017, 267-273
13. Patitsa M, Karathanou K, Kanaki Z, Tzioga L, Pippa N, et al. (2017) Magnetic nanoparticles coated with polyarabic acid demonstrate enhanced drug delivery and imaging properties for cancer theranostic applications. Scientific reports 7: 775.
14. Cho M, Cervadoro A, Ramirez MR, Stigliano C, Brazdekis A, et al. (2017) Assembly of Iron Oxide Nanocubes for Enhanced Cancer Hyperthermia and Magnetic Resonance Imaging. Nanomaterials (Basel) 7: 72. [Crossref]
15. Shiraishi K, Wang Z, Kokaryo D, Aoki I, Yokoyama M (2017) A polymeric micelle magnetic resonance imaging (MRI) contrast agent reveals blood–brain barrier (BBB) permeability for macromolecules in cerebral ischemia-reperfusion injury. J Control Release 253: 165-171. [Crossref]
16. El-Hammadi MM, Arias JL. (2015) Iron oxide-based multifunctional nanoparticulate systems for biomedical applications: a patent review (2008 - present). Expert Opin Ther Pat 25: 691-709. [Crossref]
17. Gobbo OL, Sjaastad K, Radomski MW, Volkov Y, Prina-Mello A (2015) Magnetic Nanoparticles in Cancer Theranostics. Theranostics 5: 1249-1263. [Crossref]
18. Haja L, Guttman A (2016) The use of magnetic nanoparticles in cancer theranostics: Toward handheld diagnostic devices. Biotechnol Adv 34: 354-361. [Crossref]
19. Hijnen N, Langereis S, Grull H (2014) Magnetic resonance guided high-intensity focused ultrasound for image-guided temperature-induced drug delivery. Adv Drug Deliv Rev 72: 65-81. [Crossref]
20. Timon Hussain, Quyen T. Nguyen (2014) Molecular imaging for cancer diagnosis and surgery. Adv Drug Deliv Rev 66: 90-100. [Crossref]
21. Kozissnik B, Bohorquez AC, Dobson J, Rinaldi C (2013) Magnetic fluid hyperthermia: advances, challenges, and opportunity. Int J Hyperthermia 29: 706-714. [Crossref]
22. Oliveira H, Perez-Andres E, Thevenot J, Sandre O, Berra E, et al. (2013) Magnetic field triggered drug release from polymericers for cancer therapeutics. J Control Release 169: 165-170. [Crossref]
23. Santhosh PB, Ulrich NP (2013) Multifunctional superparamagnetic iron oxide nanoparticles: promising tools in cancer theranostics. Cancer Lett 336: 8-17. [Crossref]
24. Shete PB, Patil RM, Ningebouram RS, Ghosh SJ, Pawar SH (2013) Magnetic core–shell structures for magnetic fluid hyperthermia therapy application. New Journal of Chemistry 37: 3784.
25. Zhang L, Dong WF, Sun HB (2013) Multifunctional superparamagnetic iron oxide nanoparticles: design, synthesis and biomedical photonic applications. Nanoscale 5: 7664-7684. [Crossref]
26. Zhu L, Wang D, Wei X, Zha X, Li J, et al. (2013) Multifunctional pH-sensitive superparamagnetic iron-oxide nanocomposites for targeted drug delivery and MR imaging. J Control Release 169: 228-238. [Crossref]
27. Gullapalli RP, Mazzitelli CL, et al. (2015) Polyethylene glycols in oral and parenteral formulations—A critical review. Int J Pharm 496: 219-239. [Crossref]
28. Mehvar R (2000) Dextran for targeted and sustained delivery of therapeutic and imaging agents. J Control Release 69: 1-25. [Crossref]
29. Yang H, Chen Y, Chen Z, Geng Y, Xie X, et al. (2017) Chemo-phosphodynamic combined gene therapy and dual-modal cancer imaging achieved by pH-responsive alginate/chitosan multilayer-modified magnetic mesoporous silica nanocomposites. Biomater Sci 5: 1001-1013. [Crossref]
30. Pandey AP, Sawant KK (2016) Polyethyleneimine: A versatile, multifunctional non-viral vector for nucleic acid delivery. Mater Sci Eng C Mater Biol Appl 68: 904-918. [Crossref]
31. Rudra Pratap Singh, H.V., Gangadharpappa, K. Mrunthuayana (2017) Phospholipids: Unique carriers for drug delivery systems. Journal of Drug Delivery Science and Technology 39: 166-179.
32. Sun Y, Cao L, Sheng X, Chen J, Zhou Y, et al. (2017) WRD79 promotes the proliferation of non-small cell lung cancer cells via USP7-mediated
regulation of the Mdm2-p53 pathway. *Cell Death Dis* 8: e2743. [Crossref]

33. Wen G, Qu XX, Wang D, Chen XX, Tian XC, et al. (2016) Recent advances in design, synthesis and bioactivity of paclitaxel-mimics. *Fitoterapia*, 110: 26-37. [Crossref]

34. Dah-Shyong Yu, Hui-Yu Yan, Chia-Lun Wu, Shun-Hsing Hung (2016) Comparison of therapeutic efficacy of lipo-doxorubicin and doxorubicin in treating bladder cancer. *Urological Science*.

35. Yin J, Niu Y, Shao B (2017) Products of methotrexate during chlorination. *J Environ Sci (China)* 55: 100-108. [Crossref]

36. Suthiwangcharoen N, Nagarajan R (2017) Nanoarmoring of Proteins by Conjugation to Block Copolymer Micelles. *Methods Enzymol* 590: 277-304. [Crossref]

37. Tran TT, Tran PH, Yoon TJ, Lee BJ (2017) Fattigation-platform theranostic nanoparticles for cancer therapy. *Mater Sci Eng C Mater Biol Appl* 75: 1161-1167. [Crossref]

38. Wright N, Rida PCG, Aneja R (2017) Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer. *Front Biosci (Landmark Ed)* 22: 1549-1580. [Crossref]

39. Zheng M, Zhao P, Luo Z, Gong P, Zhang P, et al. (2014) The application of nanotechnology in cancer theranostics. *Chinese Science Bulletin (Chinese Version)* 59: 3009.

40. Van S, Das SK, Wang X, Feng Z, Jin Y, et al. (2010) Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)-paclitaxel nanoconjugate. *Int J Nanomedicine* 5: 825–837. [Crossref]

41. Pearce AK, Rolfe BE, Russell PI, Tse BWC, Whittaker AK, et al. (2014) Development of a polymer theranostic for prostate cancer. *Polym Chem* 5: 6932-6942.

42. Singh M, Harris-Birtill DC, Markar SR, Hanna GB, Elson DS (2015) Application of gold nanoparticles for gastrointestinal cancer theranostics: A systematic review. *Nanomedicine* 11: 2083-2098. [Crossref]